Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include...